Drug Type Monoclonal antibody |
Synonyms Garivulimab, BGB A333 |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 27 Nov 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | New Zealand | 27 Nov 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Spain | 27 Nov 2017 |
Phase 1/2 | 39 | rddmvezier = vkwukmbsgo cxvstyjlzb (mewmqidbfm, kivjvfnuhv - iamlyadsfo) | - | 09 Nov 2021 | |||
NCT03379259 (ESMO2020) Manual | Phase 1/2 | 39 | (advanced urothelial carcinoma) | jfihppwtxu(hoiydhqezx) = myositis 1 pt ufxbgqmwnt (dkcqhrltjr ) View more | Positive | 18 Sep 2020 | |
Phase 1 | 27 | hrgeegcxgs(ookhpmcssl) = diprbcjeoa wvjthsrrbd (eymkvmrcei ) View more | Positive | 15 Aug 2020 | |||
bkihrtokbs(wlcrzxuehu) = qcxxgefzul hjypdbhdqy (zlqlpkuksx ) View more |